Bristol-Myers Squibb Co (BMY)

盈利方式

Revenue comes almost entirely from selling patented medicines. BMS sells mainly to a handful of wholesalers and distributors, plus specialty pharmacies, and to a lesser extent directly to retailers, hospitals, clinics and government agencies; the wholesalers then resell to pharmacies and providers. The price actually collected is well below list price: the company grants rebates and discounts to public programmes (Medicare, Medicaid, the 340B programme) and to private payers, and these deductions are netted against gross sales. A single product enjoys high margins while it is protected by patents and regulatory exclusivity, then revenue falls very fast once generics or biosimilars arrive — so the business is a rolling sequence of launches that must replace medicines going off patent. Royalties on out-licensed intellectual property and alliance income are a smaller, but meaningful, additional line.

分部营收

The advantage rests on intangibles: patents, regulatory exclusivity, clinical trial data and the approvals themselves, which keep competitors out of a medicine for a defined number of years. It is real but time-limited, and the 10-K says so plainly: most of a product's commercial value is captured during the exclusivity period, and when generics or biosimilars arrive revenues fall very substantially and very fast. The 2025 figures show the mechanism at work — Revlimid fell 49% to $3.0 billion while the newer portfolio grew 17%. What would make the moat durable is the research engine that keeps producing replacements, and that is a bet on future trials rather than a protection already in hand.

Demand for oncology, haematology and cardiovascular medicines follows illness, not the economy: patients start and continue treatment through recessions, and the prescriptions are largely paid by insurers and public programmes. What moves BMS's revenue is not the business cycle but the patent cycle — how many patients a new medicine reaches, and when an old one meets generic competition. The 2025 accounts show exactly that: total revenues were essentially flat at $48.2 billion while a 17% rise in the Growth Portfolio offset a 15% fall in the Legacy Portfolio. Two further drivers are political rather than economic: reimbursement decisions by payers and the rebates and price caps imposed by governments.

主要风险

• Losing market exclusivity earlier than expected — The company states that when exclusivity expires and generics or biosimilars are approved, there are usually very substantial and rapid declines in a product's revenues. Patents on key products are regularly challenged in litigation and patent-office proceedings, competitors sometimes launch 'at risk' before litigation ends, and BMS gives no assurance that any product will keep exclusivity for the full period assumed in its own estimates and guidance.
• Pricing pressure and government price setting — BMS discloses that market-access constraints, mandatory rebates and discounts in the US, the EU and elsewhere continue to reduce revenues and profit margins. Under the Inflation Reduction Act, the US Department of Health and Human Services can effectively set prices for certain single-source medicines reimbursed under Medicare. In December 2025 the company announced an agreement with the US government that includes supplying Eliquis free to Medicaid from January 2026 and offering several medicines direct to cash-paying patients at around 80% off list price. It also cites expanded use of the 340B programme and state-level drug-pricing measures.
• Dependence on a few key products — The company says it derives a majority of its revenue and earnings from several key products, and expects Eliquis, Opdivo, Opdivo Qvantig, Orencia, Reblozyl and Yervoy to represent a significant percentage of revenue, earnings and cash flows over the next few years. A fall in any of them, from loss of exclusivity or other causes, would hit earnings and cash flow.
• Research may not replace what is lost — BMS notes the high rate of failure inherent in drug research: investments in research programmes may generate no financial return, approvals may be delayed or denied, extensions and new indications may not be granted, and accelerated approvals depend on confirmatory studies that may fail. It must keep a continuous flow of new products sufficient both to cover its R&D costs and to replace sales lost to patent expiry.
• Debt taken on for acquisitions — The company lists significant indebtedness among its risk factors and refers to the substantial debt incurred to finance the cash portion of acquisitions, most recently Mirati, Karuna and RayzeBio. It also warns that the revenues, profits and cash flows of an acquired company's products and pipeline may not materialise, because of low uptake, delayed or missed pipeline opportunities, safety or regulatory issues or synergies that fail to appear.
• Supply chain and third parties — BMS discloses the risk of difficulties, delays and disruptions in its supply chain and in the manufacturing, distribution and sale of its products, and a separate risk that third parties may fail to meet their contractual, regulatory and other obligations — relevant for a company that relies on external manufacturers, alliance partners and a small number of distributors.

主要客户占营收的87%

In 2025 three wholesale distributors accounted for 87% of revenues: McKesson 36%, Cencora 29% and Cardinal Health 22% (34%, 29% and 22% respectively in 2024). This is distribution concentration rather than end-demand concentration — the wholesalers buy and resell to thousands of pharmacies, hospitals and clinics, so the patients are dispersed even though the invoices are not. It still means a very small number of counterparties carry most of the group's receivables and set much of the commercial terms in the US channel.